retrospect
analyz
data
patient
central
nervou
system
lymphoma
receiv
highdos
chemotherapi
autolog
stem
cell
transplant
use
tbc
thiotepa
busulfan
cyclophosphamid
condit
progressionfre
overal
surviv
rate
respect
toxic
includ
nauseavomit
diarrhea
mucos
febril
neutropenia
treatmentrel
mortal
first
day
transplant
data
support
use
consolid
autolog
stem
cell
transplant
patient
primari
secondari
central
nervou
system
lymphoma
background
highdos
chemotherapi
hdc
autolog
stem
cell
transplant
asct
investig
patient
primari
central
nervou
system
lymphoma
pcnsl
nonhodgkin
lymphoma
nhl
cn
involv
shown
promis
result
patient
method
retrospect
analysi
perform
consecut
patient
undergon
hdcasct
tbc
thiotepa
busulfan
cyclophosphamid
condit
pcnsl
patient
secondari
cn
lymphoma
scnsl
patient
relaps
diseas
cn
involv
patient
juli
decemb
patient
pcnsl
undergon
asct
first
complet
remiss
result
progressionfre
surviv
pf
rate
confid
interv
ci
overal
surviv
os
rate
ci
among
patient
pf
os
rate
patient
pcnsl
ci
ci
respect
univari
analysi
patient
pcnsl
asct
variabl
statist
signific
outcom
p
pf
p
os
among
patient
scnsl
cn
relaps
pf
os
rate
compar
ci
ci
respect
common
side
effect
febril
neutropenia
infecti
etiolog
identifi
nauseavomit
diarrhea
mucos
electrolyt
abnorm
four
patient
die
treatmentrel
overwhelm
infect
patient
primari
central
nervou
system
cn
lymphoma
pcnsl
nonhodgkin
lymphoma
nhl
cn
involv
histor
carri
poor
prognos
howev
increas
efficaci
induct
chemotherapi
addit
consolid
therapi
result
improv
recent
year
although
highdos
methotrex
hdmtx
alon
combin
agent
becom
mainstay
induct
therapi
optim
consolid
strategi
yet
establish
consolid
wholebrain
radiat
therapi
wbrt
use
howev
given
low
surviv
benefit
high
risk
neurotox
approach
effort
ensu
identifi
altern
option
highdos
chemotherapi
hdc
autolog
stem
cell
transplant
asct
investig
postremiss
consolid
relaps
diseas
promis
result
hdmtxebas
induct
regimen
follow
asct
variou
condit
regimen
includ
beam
carmustin
etoposid
cytarabin
melphalan
thiotepa
busulfan
tbc
thiotepa
busulfan
cyclophosphamid
thiotepa
carmustin
evalu
data
thu
far
howev
limit
singlearm
phase
ii
trial
sever
import
question
remain
includ
best
candid
therapi
time
use
possibl
toxic
optim
condit
regimen
perform
singl
institut
retrospect
analysi
consecut
patient
pcnsl
secondari
cn
lymphoma
scnsl
relaps
cn
lymphoma
undergon
consolid
asct
tbc
condit
base
earli
experi
use
regimen
patient
method
patient
juli
decemb
data
patient
nhl
undergon
asct
tbc
condit
regimen
univers
california
lo
angel
retrospect
review
three
group
patient
includ
pcnsl
defin
lymphoma
confin
cn
includ
intraocular
lymphoma
scnsl
defin
lymphoma
system
diseas
cn
involv
cn
relaps
defin
initi
diagnosi
system
lymphoma
follow
relaps
cn
without
system
involv
relaps
patient
scnsl
cn
relaps
group
togeth
patient
system
lymphoma
cn
involv
whether
found
initi
diagnosi
relaps
primari
analysi
includ
pcnsl
patient
undergon
asct
first
complet
remiss
patient
scnsl
cn
involv
relaps
analyz
separ
patient
pcnsl
uniform
induct
therapi
given
consist
rituximab
mgm
hdmtx
gm
follow
rituximab
mgm
cytarabin
gm
thiotepa
mgm
accord
report
data
number
cycl
rituximab
hdmtx
rituximabcytarabinethiotepa
determin
physician
prefer
dosag
adjust
physician
discret
organ
toxic
toler
andor
function
statu
patient
scnsl
relaps
diseas
varieti
chemotherapi
regimen
use
clinician
discret
goal
achiev
cr
asct
tabl
remiss
statu
assess
use
magnet
reson
imag
andor
positron
emiss
tomographi
brain
transplant
ultim
interpret
treat
physician
hdc
asct
consist
thiotepa
mgm
daili
dose
day
busulfan
mgkg
everi
hour
dose
day
cyclophosphamid
mgkg
daili
dose
day
mesna
previous
describ
soussain
et
al
phenytoin
mg
daili
given
seizur
prophylaxi
day
peripher
blood
stem
cell
mobil
collect
per
institut
protocol
toxic
assess
via
medic
record
review
neutrophil
platelet
recoveri
assess
accord
center
intern
blood
marrow
transplant
research
avail
http
wwwcibmtrorgdatamanagementtrainingrefer
manualsdatamanagementdocumentsposttedinstructionpdf
neutrophil
engraft
defin
first
consecut
day
absolut
neutrophil
count
cellsmm
platelet
recoveri
defin
first
consecut
day
platelet
count
day
last
platelet
transfus
treatmentrel
mortal
trm
defin
death
caus
diseas
relaps
within
day
asct
kaplanmei
method
use
plot
surviv
curv
progressionfre
surviv
pf
defin
date
asct
date
relaps
progress
death
caus
overal
surviv
os
calcul
date
asct
death
caus
date
diseas
progress
assign
use
date
imag
studi
biopsi
avail
confirm
diseas
progress
data
summar
mean
ae
standard
deviat
median
interquartil
rang
number
group
percentag
group
accord
distribut
data
univari
comparison
diagnos
perform
use
fisher
exact
test
discret
data
wilcoxon
rank
sum
asct
use
tbc
condit
cn
lymphoma
test
continu
data
os
pf
model
use
cox
proport
hazard
model
summar
use
hazard
ratio
hr
confid
interv
ci
timetoev
data
summar
use
kaplanmei
curv
hypothes
p
consid
indic
statist
signific
analys
complet
use
r
statist
comput
environ
r
core
team
r
foundat
vienna
austria
juli
decemb
consecut
patient
nhl
identifi
undergon
asct
tbc
condit
patient
pcnsl
intraocular
lymphoma
either
relaps
diseas
cn
involv
patient
scnsl
patient
chemotherapi
regimen
use
patient
asct
list
tabl
patient
pcnsl
undergon
asct
receiv
induct
therapi
rituximabhdmtx
variou
number
cycl
determin
treat
physician
median
rang
follow
rituximabcytarabinethiotepa
median
rang
one
patient
pcnsl
receiv
thiotepa
rituximabcytarabin
unclear
reason
patient
relaps
refractori
diseas
asct
receiv
addit
therapi
includ
temozolomid
patient
topotecan
patient
addit
extra
cycl
rituximabhdmtx
rituximabcytarabin
thiotepa
patient
scnslcn
relaps
receiv
varieti
therapi
asct
includ
rchop
rituximab
cyclophosphamid
doxorubicin
vincristin
prednison
patient
repoch
rituximab
etoposid
prednison
vincristin
cyclophosphamid
doxorubicin
patient
rdhap
rituximab
dexamethason
cytarabin
cisplatin
patient
addit
regimen
includ
rdhaox
rituximab
dexamethason
highdos
cytarabin
oxaliplatin
hypercvad
cyclophosphamid
vincristin
doxorubicin
dexamethason
choep
cyclophosphamid
doxorubicin
vincristin
etoposid
prednison
temozolomid
belinostat
hdmtx
patient
hdcytarabin
patient
rchop
repoch
rdhap
also
given
intrathec
chemotherapi
itmtx
intrathec
methotrex
andor
intrathec
cytarabin
administ
patient
median
number
cycl
hdmtx
patient
rang
median
number
cycl
cytarabin
thiotepa
patient
rang
three
patient
receiv
asct
use
tbc
condit
cn
lymphoma
wbrt
asct
includ
patient
pcnsl
without
remiss
induct
chemotherapi
patient
cn
relaps
kaplanmei
curv
pf
os
display
figur
asctrel
toxic
occur
tbc
condit
regimen
list
tabl
median
interv
neutrophil
recoveri
platelet
recoveri
day
iqr
day
day
iqr
day
respect
patient
experienc
febril
neutropenia
despit
data
support
use
hdcasct
patient
nhl
involv
cn
postremiss
consolid
relapsedrefractori
set
sever
unansw
question
remain
regard
ideal
patient
candid
optim
condit
time
transplant
furthermor
efficaci
toxic
compar
wbrt
nonmyeloabl
chemotherapi
incomplet
character
studi
evalu
hdcasct
postremiss
relapsedrefractori
set
use
uniform
tbc
prepar
regimen
accord
previous
report
data
soussain
et
al
aim
provid
insight
identifi
patient
might
benefit
therapi
first
trial
examin
hdcasct
pcnsl
use
beam
carmustin
etoposid
cytarabin
melphalan
condit
regimen
disappoint
result
abrey
et
al
report
relaps
rate
median
month
transplant
use
beam
condit
colombat
et
al
report
project
eventfre
surviv
ef
rate
year
project
os
rate
year
result
part
attribut
limit
penetr
bloodebrain
barrier
beam
chemotherapi
led
trial
investig
busulfan
thiotepa
report
cn
penetr
altern
myeloabl
agent
studi
tbc
shown
higher
efficaci
beam
condit
omuro
et
al
report
pf
os
rate
ci
ci
year
asct
patient
pcnsl
respect
chen
et
al
report
pf
os
rate
ci
ci
year
asct
cohort
patient
pcnsl
scnsl
respect
data
add
find
diseas
control
surviv
rate
compar
report
studi
pf
rate
ci
os
rate
ci
subset
patient
pcnsl
undergon
asct
data
might
even
favor
institut
report
pf
os
rate
ci
result
mimic
data
report
defilipp
et
al
note
pf
os
year
patient
pcnsl
undergon
transplant
furthermor
univari
analysi
data
patient
pcnsl
asct
variabl
statist
signific
pf
hr
ci
p
os
hr
ci
p
data
surpris
given
clear
surviv
benefit
lower
relaps
rate
patient
nhl
cr
asct
patient
scnsl
cnsrelaps
nhl
undergon
asct
tbc
condit
pf
os
rate
studi
ci
ci
respect
find
equival
superior
result
report
studi
compar
favor
result
patient
relapsedrefractori
pcnsl
intraocular
lymphoma
subset
analysi
patient
scnsl
undergon
hdcasct
also
tbc
condit
chen
et
al
report
pf
os
ci
ci
respect
anoth
studi
quall
et
al
patient
scnsl
also
undergon
hdcasct
tbc
condit
report
pf
os
rate
ci
ci
respect
given
cn
involv
nhl
histor
associ
poor
outcom
data
encourag
demonstr
hdcasct
safe
efficaci
patient
maziarz
et
al
conduct
larg
analysi
patient
note
compar
longterm
outcom
patient
nhl
without
cn
involv
undergon
asct
studi
report
less
impress
result
note
ef
rate
ae
os
rate
ae
year
patient
scnsl
undergon
hdc
asct
carmustin
etoposid
cyclophosphamid
condit
diseasefre
surviv
rate
ae
year
patient
scnsl
undergon
hdcasct
tbc
condit
howev
studi
includ
patient
activ
cn
diseas
known
result
poorer
outcom
patient
cn
lymphoma
remiss
patient
scnslcn
relaps
studi
studi
chen
et
al
quall
et
al
undergon
transplant
cr
like
contribut
favor
surviv
outcom
one
concern
tbc
regimen
nonhematolog
toxic
common
therapyrel
toxic
note
studi
use
regimen
febril
neutropenia
mucos
diarrhea
studi
also
found
high
rate
nauseavomit
electrolyt
abnorm
incid
septic
complic
tbc
condit
appear
greater
condit
regimen
also
led
higher
rate
treatmentrel
mortal
studi
trm
rate
septic
complic
institut
report
rang
tbc
condit
patient
pcnsl
reason
increas
toxic
clear
although
studi
found
age
year
factor
other
found
associ
scordo
et
al
hypothes
high
trm
rate
might
secondari
busulfan
level
greater
therapeut
rang
howev
found
patient
elev
firstdos
busulfan
area
curv
valu
experi
toxic
given
cn
penetr
cyclophosphamid
much
lower
achiev
thiotepa
busulfan
addit
benefit
unclear
might
instead
contribut
increas
toxic
four
patient
develop
hemorrhag
cystiti
studi
one
studi
montemurro
et
al
examin
thiotepa
busulfan
without
cyclophosphamid
condit
postremiss
consolid
patient
estim
ef
longterm
followup
studi
show
os
rate
report
greater
relaps
rate
patient
report
studi
tbc
condit
also
high
trm
patient
neurotox
occur
patient
undergon
wbrt
although
case
report
patient
undergon
asct
without
previou
wbrt
therefor
data
thu
far
show
superior
outcom
remov
cyclophosphamid
tbc
condit
regimen
howev
given
studi
examin
thiotepa
busulfan
alon
small
sampl
size
patient
true
benefit
cyclophosphamid
remain
undetermin
altern
option
cnsdirect
condit
regimen
combin
carmustin
thiotepa
carmustin
anoth
agent
substanti
cn
penetr
although
high
busulfan
two
studi
illerhau
et
al
evalu
condit
regimen
favor
result
one
studi
report
pf
os
rate
year
second
studi
report
project
pf
rate
os
rate
year
studi
report
trm
make
regimen
anoth
promis
treatment
option
discuss
detail
subsequ
paragraph
condit
regimen
carmustin
thiotepa
also
evalu
random
studi
intern
extranod
lymphoma
studi
report
os
trm
metaanalysi
hdcasct
pcnsl
found
carmustinethiotepa
condit
regimen
lowest
risk
trm
howev
tbc
regimen
numer
superior
pf
os
rate
neurotox
appear
less
common
hdcasct
wbrt
consolid
found
rate
revers
neurotox
commonli
consist
delirium
rare
seizur
scordo
et
al
report
similar
find
neurotox
patient
includ
delirium
seizur
anxietydepress
neuropathi
syncop
headach
mania
undergon
hdcasct
longterm
neurotox
effect
evalu
studi
although
report
document
delay
effect
howev
rate
longterm
neurotox
effect
appear
lower
wbrt
report
cumul
incid
neurotox
studi
sever
limit
includ
limit
sampl
size
retrospect
natur
although
precis
data
number
patient
receiv
hdcasct
vast
major
patient
diagnos
initi
therapi
ultim
undergo
asct
experi
rare
patient
diagnos
candid
asct
receiv
induct
salvag
therapi
achiev
best
respons
addit
although
patient
pcnsl
underw
asct
receiv
uniform
induct
regimen
patient
refractori
relaps
pcnsl
scnslcn
receiv
heterogen
induct
salvag
therapi
tabl
make
definit
conclus
efficaci
hdcasct
cohort
patient
difficult
final
toxic
evalu
perform
use
common
terminolog
advers
event
object
score
system
toxic
arbitrarili
defin
use
medic
record
review
also
longterm
neurotox
effect
minim
residu
diseas
statu
evalu
sever
random
clinic
trial
investig
role
hdcasct
consolid
therapi
compar
wbrt
nonmyeloabl
chemotherapi
preci
trial
includ
patient
age
year
patient
random
hdcasct
tbc
condit
induct
chemotherapi
n
pf
ci
compar
ci
receiv
wbrt
n
howev
os
year
similar
arm
vs
trm
rate
greater
hdcasct
group
death
vs
death
wbrt
group
cognit
impair
document
wbrt
howev
cognit
function
improv
remain
stabl
hdc
asct
trial
compar
wbrt
n
patient
versu
asct
n
patient
carmustinethiotepa
condit
consolid
show
similar
pf
wbrt
vs
asct
p
os
wbrt
vs
asct
p
trm
rate
asct
group
nonsignific
trend
toward
impair
attent
execut
function
year
therapi
given
wbrt
nonmyeloabl
chemotherapi
trial
process
calgb
cancer
leukemia
group
b
trial
compar
doseintens
etoposid
cytarabin
chemotherapi
hdcasct
use
carmustin
thiotepa
condit
european
compar
consolid
chemotherapi
consist
rdevic
rituximab
dexamethason
etoposid
ifosfamid
carboplatin
hdcasct
use
thiotepa
carmustin
condit
data
also
avail
use
novel
agent
target
compon
bcell
receptor
pathway
ie
bruton
tyrosin
kinas
inhibitor
ibrutinib
immunomodulatori
drug
eg
lenalidomid
pomalidomid
agent
shown
promis
high
respons
rate
current
test
salvag
set
overal
result
support
use
hdcasct
cnsdirect
condit
consolid
therapi
pcnsl
longterm
efficaci
manag
side
effect
patient
pcnsl
undergon
asct
appear
surviv
benefit
compar
patient
undergon
asct
data
scnsl
relaps
set
also
appear
encourag
longer
followup
comparison
consolid
therapi
provid
insight
report
near
futur
hdc
asct
investig
patient
pcnsl
nhl
cn
involv
postremiss
consolid
relaps
set
promis
result
studi
includ
patient
pcnsl
patient
scnslcn
relaps
patient
undergon
hdc
asct
tbc
condit
patient
pcnsl
undergon
asct
overal
data
shown
encourag
longterm
efficaci
pf
rate
ci
os
rate
ci
patient
pf
os
rate
patient
pcnsl
ci
ci
respect
appear
pf
os
benefit
patient
pcnsl
undergo
transplant
compar
undergo
transplant
beyond
pf
hr
ci
p
os
hr
ci
p
common
side
effect
febril
neutropenia
infect
nauseavomit
diarrhea
mucos
electrolyt
abnorm
die
treatmentrel
overwhelm
infect
revers
neurotox
occur
patient
studi
add
increas
data
suggest
encourag
diseas
control
surviv
hdcasct
cnsdirect
condit
pcnsl
secondari
cn
nhl
random
trial
ongo
compar
hdcasct
consolid
therapi
includ
wbrt
nonmyeloabl
chemotherapi
